American Journal of Cardiology
Volume 106, Issue 6 , Pages 787-792 , 15 September 2010

Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy

  • Michel Farnier, MD, PhD

      Affiliations

    • Point Medical, Dijon, France
    • Corresponding Author InformationCorresponding author: Tel: 33-3-80-70-38-13; fax: 33-3-80-70-38-14
    • ,
  • Jean Ducobu, MD

      Affiliations

    • University of Mons, Mons, Belgium
    • ,
  • Leszek Bryniarski, MD, PhD

      Affiliations

    • Institute of Cardiology and Jagiellonian University Medical College, Kraków, Poland

Received 3 March 2010 ,Revised 6 May 2010 ,Accepted 6 May 2010.

References 

  1. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  2. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI Trial). Am J Cardiol. 2005;95:462–468
  3. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidemia. Diabetes Res Clin Pract. 2004;64:137–151
  4. Farnier M. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative (A critical review of potential benefits and drawbacks). Am J Cardiovasc Drugs. 2003;3:169–178
  5. Fruchart J-C, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(suppl):1K–34K
  6. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(suppl):3C–18C
  7. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005;96(suppl):44K–49K
  8. Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol. 2009;5:507–518
  9. Pan W-J, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. 2000;40:316–323
  10. Gustavson LE, Schweitzer SM, Koehne-Voss S, Achari R, Chira TO, Esslinger H-U, et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3α-hydroxy isomeric metabolite. J Clin Pharmacol. 2005;45:947–953
  11. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9975 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861
  12. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vasc Health Risk Manag. 2008;4:991–1000
  13. Keating GM, Croom KF. Fenofibrate (A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus). Drugs. 2007;67:121–153
  14. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574

 This study was supported by Laboratories SMB, Brussels, Belgium.

 Dr Farnier has received grant/research support and speaker’s honoraria from and served as a consultant and advisor for Astra-Zeneca (Rueil-Malmaison, France), Genzyme (St Germain-en-Laye, France), Kowa (Nagoya, Japan), Merck and Co (Whitehouse Station, New Jersey), Merck-Schering-Plough (North Wales, Pennsylvania), Novartis (Rueil-Malmaison, France), Pfizer (Paris, France), Sanofi-Aventis (Paris, France), SMB (Brussels, Belgium), Solvay (Suresnes, France) and Takeda (Paris, France). Dr Ducobu has received grant/research support and speaker’s honoraria from and served as a consultant and advisor for Astra-Zeneca (Cheshire, United Kingdom), GSK (Genval, Belgium), Lilly (Brussels, Belgium), Merck and Co, Merck-Schering-Plough, Pfizer (New York, New York), Sandoz (Cham, Switzerland), Sanofi-Aventis, SMB and Solvay (Ixelles, Belgium). Dr Bryniarski has received speaker’s honoraria from Merck and Co, Servier (Neuilly-sur-seine, France), Merck-Schering-Plough, Sanofi-Aventis and Solvay.

PII: S0002-9149(10)01041-6

doi: 10.1016/j.amjcard.2010.05.005

American Journal of Cardiology
Volume 106, Issue 6 , Pages 787-792 , 15 September 2010

Article Tools

* Image Usage & Resolution